Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Evrofarma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
€1.5
2024-10-29
Market Capitalization
€20.6 M
2024-10-29
Revenue
€49.4 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32.5M | 33.5M | 33.9M | 36.8M | 45.4M | 48.8M | 45.7M | 49.4M |
| Cost of goods sold | 19.4M | 20.6M | 22.1M | 32.6M | 30.4M | 39.4M | 27.6M | 29.3M |
| Gross profit | 15.3M | 13.5M | 13.1M | 5.4M | 16.1M | 10.4M | 19.4M | 21.4M |
| Gross profit margin, % | 47.1% | 40.5% | 38.7% | 35.4% | 21.3% | 42.4% | 43.2% | |
| Operating expense total | 11.5M | 9.4M | 9.7M | 4.8M | 12.0M | 4.1M | 12.8M | 14.1M |
| Depreciation and amortization | 1.4M | 1.1M | 1.4M | 1.5M | 2.1M | 1.8M | 2.0M | |
| EBITDA | 3.8M | 4.1M | 3.4M | 558.0K | 4.1M | 6.4M | 6.6M | 7.3M |
| EBITDA margin, % | 11.7% | 12.3% | 10.0% | 8.9% | 13.0% | 14.4% | 14.8% | |
| EBIT | 2.1M | 2.6M | 2.0M | 558.0K | 2.5M | 4.4M | 4.8M | 5.4M |
| EBIT margin, % | 6.5% | 7.7% | 6.0% | 5.6% | 9.0% | 10.5% | 10.8% | |
| Interest income | 43.0K | 240.0K | 40.0K | |||||
| Interest expense | 865.0K | 2.3M | 880.0K | 818.0K | 916.0K | 1.4M | 1.2M | 737.0K |
| Pre tax profit | 1.3M | 326.0K | 1.2M | (260.0K) | 1.5M | 2.7M | 2.9M | 4.5M |
| Income tax expense | 282.0K | 169.0K | 115.0K | 95.0K | 103.0K | 505.0K | 608.0K | 1.0M |
| Net Income | 979.0K | 157.0K | 1.1M | (355.0K) | 1.4M | 2.2M | 2.3M | 3.5M |